Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
July 2012, Vol 3, No 5
July 2012, Vol 3, No 5
Quality of Life Drives Patient Preference for Metastatic Renal-Cell Carcinoma Drug
By
Wayne Kuznar
ASCO Annual Meeting
,
ASCO
July 2012, Vol 3, No 5
Chicago, IL—The surprising results of a randomized trial on patient preference for one cancer therapy over another show that patient-reported quality-of-life (QOL) differences influence treatment preference far more than physicians had imagined, suggested researchers at the 2012 American Society of Clinical Oncology meeting.
Read Article
Is Pemetrexed/Platinum Therapy Cost-Effective in NSCLC?
By
Audrey Andrews
AMCP Annual Meeting
July 2012, Vol 3, No 5
San Francisco, CA—In what appears to be the first study to use real-world, non–clinical trial data to evaluate the cost-effectiveness of pemetrexed/platinum (Pem/P) therapy used first line in patients with advanced non–smallcell lung cancer (NSCLC), this combination trended toward being more effective and less costly than carboplatin/ paclitaxel plus bevacizumab (C/Pa+B), reported Manan Shah, PharmD, PhD, with Xcenda, Palm Harbor, FL, and colleagues at the 2012 Academy of Managed Care Pharmacy annual meeting.
Read Article
In Colorectal Cancer, Treatment Efficacy Is High Among the Elderly
By
Caroline Helwick
AMCP Annual Meeting
July 2012, Vol 3, No 5
San Francisco, CA—The vast majority of published evidence indicates that the relative treatment effect of chemotherapy for stage III colon cancer is as good for elderly patients as it is for younger ones, according to a systematic literature review by Anna Hung, a student in the program, and C. Daniel Mullins, PhD, Professor, Pharmacoeconomics, Pharmaceutical Health Services Research Department, Associate Director, Center on Drugs and Public Policy.
Read Article
New Test May Spare the Need for Surgery to Diagnose Thyroid Cancer
In the Literature
July 2012, Vol 3, No 5
A new geneexpression test may soon be used for the diagnosis of such nodules, which could reduce the use of diagnostic surgery in this population (Alexander EK, et al.
N Engl J Med
. Epub 2012 Jun 25).
Read Article
Childhood Cancer Survivors at Risk for GI Cancers Later in Life: Screening Recommended
In the Literature
July 2012, Vol 3, No 5
The Childhood Cancer Survivor Study included a cohort of 14,337 childhood cancer survivors (which is believed to be the largest cohort of this type) and assessed the risk for gastrointestinal (GI) malignant neoplasms in this population (Henderson TO, et al.
Ann Intern Med
. 2012;156:757-766).
Read Article
Updated USPSTF Cervical Cancer Screening Recommendations
In the Literature
July 2012, Vol 3, No 5
Cervical cancer remains an important public health issue. The US Preventive Services Task Force (USPSTF) has issued an update to its 2003 cervical cancer screening recommendations based on current evidence (Moyer VA, on behalf of the USPSTF.
Ann Intern Med
. 2012;156:880-891).
Read Article
Does CMS’s Coverage Decision for Sipuleucel-T Herald More Restrictive Policy?
AMCP Annual Meeting
July 2012, Vol 3, No 5
San Francisco, CA—In its national coverage decision (NCD) for sipuleucel-T in the treatment of advanced prostate cancer, the Centers for Medicare & Medicaid Services (CMS) left the coverage decision for any off-label use of medications to the discretion of the local Medicare contractors, citing an absence of data on which to make a coverage decision.
Read Article
Vemurafenib Does Not Impact Health Plan Budget
By
Caroline Helwick
AMCP Annual Meeting
July 2012, Vol 3, No 5
Although the upfront cost of vemurafenib is high, its use to treat patients with metastatic melanoma actually results in a costsavings per health plan member per month (PMPM), according to an analysis presented at the 2012 Academy of Managed Care Pharmacy annual meeting.
Read Article
Oncology Genetic Testing: Pharmacists’ Knowledge Gap
AMCP Annual Meeting
July 2012, Vol 3, No 5
San Francisco, CA—Knowledge of pharmacogenomics—the genomic factors contributing to individual variability in response to drug therapy (or personalized medicine)—enhances the ability to diagnose, prevent, and treat disease, especially a variety of cancers.
Read Article
Pathways Offer Providers a True Value Proposition
By
Caroline Helwick
July 2012, Vol 3, No 5
Houston, TX—“The key question on everyone’s mind is, how do we monetize the value of pathways?” said Peter G. Ellis, MD, Deputy Director of Clinical Services and Associate Chief Medical Officer, University of Pittsburgh Cancer Centers, PA, at the Second Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Page 1 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma